AZD0424
AZD0424 is an orally active, and dual selective Src/Abl kinase inhibitor with potential antineoplastic activity. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 692054-06-1
- Formel: C25H29ClN6O5
- Molecular Weight:528.99
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Src/Abl kinase inhibitor (SrcK-I), apoptosis[1]
AZD0424 (1-5 μM; 24-48 hours) is emerged to be the more effective of the three tested inhibitors (AZM559756, AZD0530 and AZD0424), inducing the highest levels of apoptosis with the lowest concentrations in lymphoma cells[2]. AZD0424 (5 μM; 48 hours) leads to increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells, whereas the cell cycle progression of the nonsensitive cell lines Raji and Jurkat remains unaffected[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DOHH-2, WSU-NHL, Raji, Jurkat, Karpas-299 and HUT78 cells
-
Concentration:1 μM; 2 μM; 3 μM; 4 μM; 5 μM;
-
Incubation Time:24 hours, 48 hours
-
Result:Induced apoptosis in lymphoma cells.
-
Cell Line:DOHH-2, WSU-NHL, Raji and Jurkat cells
-
Concentration:1 μM; 2 μM; 3 μM; 4 μM; 5 μM;
-
Incubation Time:48 hours
-
Result:Increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 692054-06-1
-
Molecular Weight 528.99
-
Formel C25H29ClN6O5
-
SMILES
CC(N1CCN(CCOC2=CC3=NC=NC(NC4=C(OCO5)C5=NC=C4Cl)=C3C(OC(C)C)=C2)CC1)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Woodcock VK, et al. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. Br J Cancer. 2018 Mar 20;118(6):770-776. [Content Brief]
[2]. Nowak D, et al. Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anticancer Drugs. 2007 Oct;18(9):981-95. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)